Alder BioPharmaceuticals to Present at 15th Annual Needham

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Alder BioPharmaceuticals to Present at 15th Annual Needham Healthcare Conference

BOTHELL, Wash., April 08, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the prevention of migraine, Congenital Adrenal Hyperplasia, Cushing’s disease and autoimmune and inflammatory diseases, today announced that it will webcast its presentation at the upcoming 15 th Annual Needham Healthcare Conference at 8:00 a.m. ET on Tuesday, April 12, 2016 in New York, NY. The presentation will feature a business overview and update by Mark J. Litton, Ph.D., Alder’s chief business officer.

A live audio webcast can be accessed on the Events & Presentations page of the Investors section of Alder’s website at http://www.alderbio.com , or by following the link below in your web browser. An archived replay of the webcast will be available on Alder’s website for 30 days after the live event concludes.

Link: http://wsw.com/webcast/needham76/aldr

About Alder BioPharmaceuticals, Inc. Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. ALD403, Alder's lead pivotal-stage product candidate being evaluated for migraine prevention, is a genetically engineered monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP). CGRP is a small protein with a well-established role in the initiation, transmission and heightened sensitivity to migraine pain. Alder's second program, ALD1613, targets adrenocorticotropic hormone (ACTH) and is intended for the treatment of Congenital Adrenal Hyperplasia and Cushing's Disease. ALD1613 is undergoing Investigational New Drug (IND)-enabling preclinical studies, and an IND submission is planned for 2016. Additionally, Alder’s clazakizumab is designed to block the pro-inflammatory cytokine IL-6 and has completed two successful Phase 2b clinical trials. Alder is seeking strategic opportunities for clazakizumab. For more information, please visit  http://www.alderbio.com . 

Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements relating to: the continued development and clinical, therapeutic and commercial potential of ALD403, ALD1613 and clazakizumab; future regulatory filings; and the pursuit of strategic opportunities for clazakizumab.  Words such as “potential,” “intended,” “planned,” “seeking,” or other similar expressions, identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The forward-looking statements in this press release are based upon Alder's current plans, assumptions, beliefs, expectations, estimates and projections, and involve substantial risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: risks related to the potential failure of ALD403, ALD1613 and clazakizumab to demonstrate safety and efficacy in clinical testing; the availability of data at the expected times; the clinical, therapeutic and commercial value of ALD403, ALD1613 and clazakizumab; risks and uncertainties related to regulatory review and approval processes and Alder's compliance with applicable legal and regulatory requirements; and other factors discussed under the caption "Risk Factors" in Alder’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, which was filed with the Securities and Exchange Commission (SEC) on February 23, 2016, and is available on the SEC's website at www.sec.gov.  Additional information will also be set forth in Alder’s other reports and filings it will make with the SEC from time to time.  The forward-looking statements made in this press release speak only as of the date of this press release.  Alder expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Alder's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Media Contacts: David Schull or Lena Evans Russo Partners, LLC (212) 845-4271 (212) 845-4262 david.schull@russopartnersllc.com lena.evans@russopartnersllc.com Investor Relations Contact: David Walsey Alder Biopharmaceuticals (425) 408-8032 ir@alderbio.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 304

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 211

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 210

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 211

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 201

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 272

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 296

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 138

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 350

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 238

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading

Top 5 Most Recently Viewed Articles

Impressive Financial Growth for Caris Life Sciences in Q2 2025

Updated Category News Views 262

Caris Life Sciences Achieves Significant Growth in Financial Results Today, Caris Life Sciences, Inc. (NASDAQ: CAI) reported remarkable financial results, highlighting a 81.3% increase in total revenue year-over-year for the second quarter of 2025. This substantial growth showcases the company's resilience and innovative approach in the ever-evolving healthcare landscape....

Continue Reading
What to Expect from Globus Maritime's Upcoming Earnings Report

Updated Category News Views 253

Anticipating Globus Maritime's Earnings Report Globus Maritime (NASDAQ: GLBS) is gearing up to unveil its quarterly earnings report soon, and investors are eager to gain insight into the company’s financial performance. This report will be a crucial indicator of the company's trajectory as it navigates the ever-changing maritime industry. Analyst Expectations for...

Continue Reading
Discover Exciting Savings with Haoqi E-Bikes This Sale

Updated Category News Views 187

Haoqi E-Bikes Launches Exciting Black Friday Sale With a profound appreciation for family and the great outdoors, Haoqi E-Bikes is thrilled to reveal its noteworthy promotion on the highly sought-after Cheetah Dual Battery Full Suspension E-Bike. From an initial launch date, the brand will provide an incredible discount of $1101 on the Cheetah model to promote outdoor...

Continue Reading
3 Unstoppable Dividend Stocks for Income Investors

Updated Category News Views 125

Finding Reliable Dividend Stocks For investors seeking income, stocks that offer stability and dependable dividends are often the preferred choice. It's generally unwise to invest in companies with uncertain futures that might reduce their dividends. Instead, savvy investors focus on resilient dividend stocks that promise steady returns and growth over time. A Dividend...

Continue Reading
Certification Boosts Aviation Capital's Boeing 737-10 Prospects

Updated Category News Views 115

Nothing like a green light from the FAA to put a little extra swagger in an aircraft lessor's step, and that's exactly what's happening with Aviation Capital Group (ACG) and their big bet on Boeing's 737-10. It's like the champagne just got popped! This milestone is no minor hurdle. We're talking about the largest addition to the 737 MAX family finally giving an official...

Continue Reading